

Date: August 25, 2025

To, The Manager-Corporate Relationship Dept. BSE Limited P.J Towers, Dalal Street, Fort, Mumbai - 400 001, India. Scrip Code: BSE - 524500	To, The Manager — Corporate Compliance Dept. National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, "G" Block Bandra - Kurla Complex, Bandra (East), Mumbai – 400051, India. Scrip Code: NSE - KILITCH
---	--

Sub: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**Ref: Allotment of Securities - Rights Issue**

Dear Sir/Madam,

In terms of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of Kilitch Drugs (India) Limited (“the Company”) has today i.e. August 25, 2025, considered and approved the allotment of 13,98,463 Equity Shares of Face Value of Rs.10/- each on Rights Basis to the eligible shareholders at an issue price of Rs.357/- per Equity Share (including a premium of Rs. 347/- per Equity Share).

The said allotment is made pursuant to the terms set out in the Letter of Offer dated July 12, 2025, and the ‘Basis of Allotment’ as finalised in consultation with the MUFG Intime India Private Limited (“Registrar to the Issue”) and as approved by National Stock Exchange of India Limited (“the Designated Stock Exchange for the Issue”). Consequent to the said allotment, the Paid-up Equity Share Capital of the Company stand modified as follows:

Particulars	No. of Shares	Face Value
Paid-up share capital (Pre-Rights Issue)	1,60,82,319	Rs. 10/-
Paid-up share capital (Post-Rights Issue)	1,74,80,782	Rs. 10/-

The meeting commenced at 8:05 PM and ended at 9:20 P.M.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”) read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 (“as amended”), are given in ‘Annexure A’ to this letter

The above information will also available on the website of the Company i.e. <https://kilitch.com/investor-relations/> .

We request you to take this on record, and to treat the same as compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For Kilitch Drugs (India) Limited

MUKUND
PRATAPRAI MEHTA

Mukund Mehta
Managing Director
DIN: 00147876



Annexure-A

Details of Issuance of securities

Sr. No.	Details of event(s) that need to be provided	Information of such event(s)
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Equity Shares
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.);	Rights Issue
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Allotment of 13,98,463 fully paid-up Equity Shares of Face Value of Rs. 10/- each on Rights Basis to the eligible shareholders and/ or renouncee(s) in terms of the Letter of Offer at an issue price of Rs. 357/- per Equity Share (including a premium of Rs. 347/- per Equity Share)
4.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable

Other details as prescribed in point (d) to (g) of clause 2.1 of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 ("as amended"), are not applicable to the Company's Right Issue.

Yours faithfully,

For **Kilitch Drugs (India) Limited**

**MUKUND
PRATAPRAI
MEHTA**

Digitally signed by MUKUND PRATAPRAI MEHTA,
DN: cn=MUKUND PRATAPRAI MEHTA,
o=Kilitch Drugs (India) Limited,
ou=Kilitch Drugs (India) Limited,
c=IN

Mukund Mehta
Managing Director
DIN: 00147876

